+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bnp & Ntprobnp Market by Type, Test Type, Component, Technology, Sales Channel, Application, End User - Global Forecast to 2030- Product Image
Bnp & Ntprobnp Market by Type, Test Type, Component, Technology, Sales Channel, Application, End User - Global Forecast to 2030- Product Image
Sale

Bnp & Ntprobnp Market by Type, Test Type, Component, Technology, Sales Channel, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083861
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bnp & Ntprobnp Market grew from USD 1.96 billion in 2024 to USD 2.18 billion in 2025. It is expected to continue growing at a CAGR of 11.30%, reaching USD 3.73 billion by 2030.

Setting the Stage for BNP and NT-proBNP Diagnostics

The executive summary of the BNP and NT-proBNP diagnostic market delves into the critical role these biomarkers play in cardiovascular care and beyond. As heart failure prevalence rises globally, the accurate quantification of B-type natriuretic peptides has become indispensable for clinicians, driving renewed interest in both established and emerging testing modalities. This analysis opens with an overview of market fundamentals, charting the trajectory of test adoption and the technological innovations that underpin growing diagnostic confidence.

In this landscape, NT-proBNP assays complement BNP test kits by offering enhanced stability and predictive prognostic value, reinforcing the clinical decision-making toolkit. Stakeholders across laboratory and point-of-care settings seek solutions that balance speed, sensitivity, and cost-effectiveness. The confluence of regulatory pressures, shifting reimbursement frameworks, and burgeoning point-of-care platforms has set the stage for transformative developments. This introduction frames the subsequent sections, preparing decision-makers to navigate both immediate challenges and long-term opportunities in the BNP and NT-proBNP market.

Navigating Transformational Forces Reshaping Diagnostics

The BNP and NT-proBNP diagnostic arena is witnessing profound shifts propelled by technological breakthroughs and evolving care delivery models. Traditional laboratory-based immunoassays are now complemented by rapid, portable platforms that enable near-patient testing. Chemiluminescent immunoassays continue to dominate high-throughput settings, yet enzyme-linked immunosorbent assays retain their relevance in research laboratories exploring biomarker validation and assay refinement.

Simultaneously, the rise of biosensor integration and microfluidic innovations is reconfiguring point-of-care testing, reducing turnaround times from hours to minutes. Diagnostic device manufacturers are investing heavily in Benchtop and portable analyzers to support decentralized testing. Reagents and kits are evolving to streamline workflows, with simplified sample preparation and automated calibration. As healthcare systems pivot toward value-based care, payers and providers demand evidence of improved patient outcomes and cost savings, setting the stage for a new era of biomarkers-driven diagnostics. This transformative phase underscores the need for nimble strategies that align with technological agility and regulatory foresight.

Overcoming 2025 Tariff Pressures on Diagnostic Supply Chains

United States tariffs imposed in 2025 have yielded a complex impact on the supply chain for BNP and NT-proBNP test components. Devices and reagents imported from affected regions faced immediate cost increases, prompting manufacturers to reevaluate sourcing strategies. Benchtop analyzers and portable devices experienced price adjustments that trickled down to reagent kit providers, intensifying pressure on end users to absorb higher operational expenses.

Laboratory testing facilities felt the burden acutely, as the incremental tariffs on sensor chips and specialized reagents disrupted long-established procurement channels. In parallel, point-of-care testing providers grappled with the rising cost of portable analyzers, compelling many to renegotiate distributor agreements and explore domestic manufacturing partnerships. To mitigate these headwinds, some companies accelerated their transition to microfluidic-based consumables that rely less on tariff-impacted components. Meanwhile, end users expanded collaborative purchasing models and regional consortia, softening the immediate financial impact. Although the tariffs have introduced short-term volatility, they have also catalyzed strategic realignments that may enhance supply chain resilience in the long term.

Unpacking Core Segmentation Trends in Biomarker Testing

An in-depth examination of market segments reveals distinct dynamics across product types and applications. BNP test kits and NT-proBNP kits each command significant attention, with clinicians selecting the optimal assay based on clinical context and patient stability. Laboratory testing remains the backbone of high-volume diagnostics, predominantly powered by chemiluminescent immunoassay platforms, while enzyme-linked immunosorbent assays continue to support specialized research endeavors evaluating novel biomarker correlations.

Within the component spectrum, analyzers and devices-both benchtop and portable-serve as critical investment areas, complemented by specialized reagents and kits designed to enhance assay sensitivity. Technological advancements in biosensors, immunoassays, and microfluidics are unlocking new possibilities for point-of-care and decentralized testing. Offline sales channels maintain strong relationships with institutional buyers, while online platforms gain traction by simplifying procurement for smaller clinics and research labs.

From a clinical perspective, heart failure management leads demand, with acute and chronic cases driving assay utilization. Cardiogenic shock and decompensated heart failure scenarios require rapid results, underscoring the need for robust point-of-care solutions. Chronic heart failure subtypes, including biventricular, left-sided, and right-sided failure with cor pulmonale, amplify the importance of longitudinal monitoring. Kidney dysfunction testing for acute kidney injury and chronic kidney disease represents a growing application, as does risk assessment for cardiovascular diseases, spanning prognostic evaluation through mortality and readmission risk analysis. Clinical laboratories, hospitals and clinics, and research institutes rely on these diagnostic solutions to inform patient care and advance scientific understanding.

Mapping Regional Adoption and Growth Dynamics

Regional dynamics underscore the varied pace of adoption and market maturation. In the Americas, established healthcare infrastructures and reimbursement frameworks facilitate widespread implementation of advanced BNP and NT-proBNP assays. The region’s strong clinical trial activity further amplifies demand for high-throughput laboratory testing and robust point-of-care solutions designed to support acute care pathways.

Europe, the Middle East, and Africa exhibit a diverse landscape where regulatory harmonization efforts and public health initiatives drive adoption in urban centers, while resource constraints in certain markets necessitate cost-effective assay formats. Localized manufacturing partnerships and regional distribution networks play an influential role in bridging the gap between innovation and accessibility.

Asia-Pacific stands out for its rapid healthcare expansion and investment in diagnostic capabilities. Countries across the region are prioritizing heart failure management programs, catalyzing demand for both benchtop analyzers and portable devices. The emphasis on digital health integration and telemedicine further accelerates uptake of decentralized testing, reinforcing the region’s position as a growth hotspot.

Analyzing Competitive Strategies and Market Positioning

Competitive intensity in the BNP and NT-proBNP market centers on innovation, strategic collaborations, and portfolio diversification. Leading diagnostic corporations are enhancing their reagent and instrument offerings through targeted acquisitions and co-development agreements, aiming to secure comprehensive solutions spanning from sample-to-result.

Major players differentiate through proprietary assay chemistries that offer enhanced sensitivity and specificity, alongside modular analyzer platforms that support multi-marker testing. Some companies focus on advancing microfluidic cartridge designs to reduce sample volumes and accelerate processing time, while others invest in cloud-enabled connectivity to facilitate remote data management and telehealth integration.

Emerging entrants leverage niche expertise in biosensor technologies and point-of-care instrumentation, forging partnerships with research institutes to validate next-generation immunoassays. These competitors aim to carve out opportunities in specialized segments such as prognostic risk assessment and kidney dysfunction monitoring. Strategic alliances between reagent suppliers and analyzer manufacturers continue to reshape the market landscape, fostering an ecosystem where end-to-end diagnostic solutions thrive.

Strategic Imperatives for Market Leadership

To capitalize on the evolving BNP and NT-proBNP market, industry leaders should prioritize agile supply chain strategies, diversifying component sourcing across multiple regions to mitigate tariff-related disruptions. Embracing technology partnerships can accelerate the development of innovative biosensor and microfluidic platforms, enabling rapid deployment of next-generation point-of-care solutions.

Investing in digital connectivity and data analytics will strengthen the value proposition for laboratory and clinical end users, as integrated diagnostic workflows become central to value-based care models. Collaborative initiatives with healthcare providers and payers to demonstrate clinical utility and cost-effectiveness can unlock new reimbursement pathways and drive broader adoption.

Finally, fostering co-development alliances with academic and research institutions will ensure continuous refinement of assay performance and expand the evidence base for novel applications. By aligning product roadmaps with emerging clinical needs in heart failure management, kidney dysfunction diagnostics, and cardiovascular risk assessment, companies can secure leadership in a market poised for sustained growth.

Ensuring Rigor through Comprehensive Research Methods

This market research employed a rigorous, multi-phase methodology to ensure comprehensive and accurate insights. Primary research included in-depth interviews with key opinion leaders, diagnostic directors, and supply chain managers across multiple geographies. These qualitative insights were complemented by quantitative data collected from leading clinical laboratories, hospitals, and point-of-care settings.

Secondary research drew on peer-reviewed journals, regulatory filings, industry white papers, and conference proceedings to track technological advancements, tariff developments, and regional policy shifts. Competitive intelligence was gathered through an analysis of corporate reports, financial statements, and patent filings, providing a lens into strategic initiatives and R&D pipelines.

Data triangulation techniques were applied to validate findings, ensuring consistency across sources. Market dynamics were mapped through scenario analysis, accounting for variables such as tariff fluctuations, regulatory changes, and emerging clinical guidelines. This robust research framework underpins the report’s accuracy and relevance, equipping stakeholders with the intelligence needed to navigate the BNP and NT-proBNP diagnostic landscape.

Charting the Path Forward in Cardiac Biomarker Diagnostics

The BNP and NT-proBNP diagnostic market is at an inflection point, shaped by technological innovation, shifting regulatory landscapes, and dynamic regional growth patterns. As the demand for rapid, accurate heart failure and kidney dysfunction assessments intensifies, stakeholders must navigate tariff pressures, competitive complexities, and evolving clinical paradigms.

By synthesizing segmentation insights, regional trends, and competitive strategies, this executive summary highlights the multifaceted nature of the market. The convergence of advanced immunoassay chemistries, portable analyzer platforms, and integrated digital solutions presents both challenges and opportunities for diagnostic manufacturers and end users.

Ultimately, success in this market will hinge on the ability to anticipate clinical needs, forge collaborative partnerships, and deliver differentiated solutions that align with value-based care objectives. The strategic imperatives outlined herein provide a roadmap for stakeholders to harness the full potential of BNP and NT-proBNP testing, driving improved patient outcomes and sustainable business growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Bnp Test Kits
    • Ntprobnp Test Kits
  • Test Type
    • Laboratory Testing
      • Chemiluminescent Immunoassay (CLIA)
      • Enzyme-linked Immunosorbent Assay (ELISA)
    • Point-of-Care Testing
  • Component
    • Analyzers & Devices
      • Benchtop Analyzers
      • Portable Analyzers
    • Reagents & Kits
  • Technology
    • Biosensors
    • Immunoassays
    • Microfluidics
  • Sales Channel
    • Offline Sales
    • Online Sales
  • Application
    • Heart Failure Management
      • Acute Heart Failure
        • Cardiogenic Shock
        • Decompensated Heart Failure
      • Chronic Heart Failure
        • Biventricular Heart Failure
        • Left-Sided Heart Failure
        • Right-Sided Heart Failure
          • Cor Pulmonale
    • Kidney Dysfunction
      • Acute Kidney Injury
      • Chronic Kidney Disease
    • Risk Assessment
      • Prognostic Evaluation
        • Mortality Risk Assessment
        • Readmission Risk Assessment
      • Screening for Cardiovascular Diseases
  • End User
    • Clinical Laboratories
      • Diagnostic Laboratories
        • Biochemistry Labs
        • Pathology Labs
      • Research Laboratories
    • Hospitals & Clinics
    • Research Institutes & Academia
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • bioMérieux PLC
  • Chengdu Illumaxbio Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio China Co., Ltd.
  • Gentian Diagnostics ASA
  • Getein Biotech, Inc.
  • QuidelOrtho Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Europe N.V.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bnp & Ntprobnp Market, by Type
8.1. Introduction
8.2. Bnp Test Kits
8.3. Ntprobnp Test Kits
9. Bnp & Ntprobnp Market, by Test Type
9.1. Introduction
9.2. Laboratory Testing
9.2.1. Chemiluminescent Immunoassay (CLIA)
9.2.2. Enzyme-linked Immunosorbent Assay (ELISA)
9.3. Point-of-Care Testing
10. Bnp & Ntprobnp Market, by Component
10.1. Introduction
10.2. Analyzers & Devices
10.2.1. Benchtop Analyzers
10.2.2. Portable Analyzers
10.3. Reagents & Kits
11. Bnp & Ntprobnp Market, by Technology
11.1. Introduction
11.2. Biosensors
11.3. Immunoassays
11.4. Microfluidics
12. Bnp & Ntprobnp Market, by Sales Channel
12.1. Introduction
12.2. Offline Sales
12.3. Online Sales
13. Bnp & Ntprobnp Market, by Application
13.1. Introduction
13.2. Heart Failure Management
13.2.1. Acute Heart Failure
13.2.1.1. Cardiogenic Shock
13.2.1.2. Decompensated Heart Failure
13.2.2. Chronic Heart Failure
13.2.2.1. Biventricular Heart Failure
13.2.2.2. Left-Sided Heart Failure
13.2.2.3. Right-Sided Heart Failure
13.2.2.3.1. Cor Pulmonale
13.3. Kidney Dysfunction
13.3.1. Acute Kidney Injury
13.3.2. Chronic Kidney Disease
13.4. Risk Assessment
13.4.1. Prognostic Evaluation
13.4.1.1. Mortality Risk Assessment
13.4.1.2. Readmission Risk Assessment
13.4.2. Screening for Cardiovascular Diseases
14. Bnp & Ntprobnp Market, by End User
14.1. Introduction
14.2. Clinical Laboratories
14.2.1. Diagnostic Laboratories
14.2.1.1. Biochemistry Labs
14.2.1.2. Pathology Labs
14.2.2. Research Laboratories
14.3. Hospitals & Clinics
14.4. Research Institutes & Academia
15. Americas Bnp & Ntprobnp Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Bnp & Ntprobnp Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Bnp & Ntprobnp Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Autobio Diagnostics Co., Ltd.
18.3.3. Beckman Coulter, Inc.
18.3.4. Bio-Rad Laboratories, Inc
18.3.5. bioMérieux PLC
18.3.6. Chengdu Illumaxbio Technology Co., Ltd.
18.3.7. F. Hoffmann-La Roche Ltd
18.3.8. Fujirebio China Co., Ltd.
18.3.9. Gentian Diagnostics ASA
18.3.10. Getein Biotech, Inc.
18.3.11. QuidelOrtho Corporation
18.3.12. Radiometer Medical ApS
18.3.13. Randox Laboratories Ltd.
18.3.14. Siemens AG
18.3.15. Sysmex Corporation
18.3.16. Thermo Fisher Scientific Inc.
18.3.17. Tosoh Europe N.V.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BNP & NTPROBNP MARKET MULTI-CURRENCY
FIGURE 2. BNP & NTPROBNP MARKET MULTI-LANGUAGE
FIGURE 3. BNP & NTPROBNP MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BNP & NTPROBNP MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BNP & NTPROBNP MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BNP & NTPROBNP MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY NTPROBNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY (CLIA), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BNP & NTPROBNP MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BNP & NTPROBNP MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CARDIOGENIC SHOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DECOMPENSATED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIVENTRICULAR HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COR PULMONALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MORTALITY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BNP & NTPROBNP MARKET SIZE, BY READMISSION RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SCREENING FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOCHEMISTRY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 101. CANADA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. CANADA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 103. CANADA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 104. CANADA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 105. CANADA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 106. CANADA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. CANADA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. CANADA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. CANADA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 110. CANADA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 111. CANADA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 112. CANADA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 113. CANADA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 114. CANADA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 115. CANADA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 116. CANADA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 118. CANADA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 119. MEXICO BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 210. GERMANY BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. GERMANY BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 213. GERMANY BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 214. GERMANY BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 215. GERMANY BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. GERMANY BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. GERMANY BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. GERMANY BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 219. GERMANY BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 220. GERMANY BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 221. GERMANY BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 222. GERMANY BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 223. GERMANY BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 224. GERMANY BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 225. GERMANY BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. GERMANY BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 227. GERMANY BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 231. FRANCE BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 232. FRANCE BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 233. FRANCE BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. FRANCE BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. FRANCE BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. FRANCE BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 237. FRANCE BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 238. FRANCE BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 240. FRANCE BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 241. FRANCE BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 242. FRANCE BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 243. FRANCE BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. FRANCE BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 245. FRANCE BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 264. ITALY BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. ITALY BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 266. ITALY BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 267. ITALY BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 268. ITALY BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 269. ITALY BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. ITALY BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ITALY BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. ITALY BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 273. ITALY BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 274. ITALY BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 275. ITALY BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 276. ITALY BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 277. ITALY BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 278. ITALY BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 279. ITALY BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. ITALY BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 281. ITALY BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 282. SPAIN BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 285. SPAIN BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 286. SPAIN BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 287. SPAIN BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. SPAIN BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SPAIN BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. SPAIN BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 291. SPAIN BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 292. SPAIN BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 295. SPAIN BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 296. SPAIN BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 297. SPAIN BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. SPAIN BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 299. SPAIN BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 328. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 332. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 339. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 340. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 341. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 342. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. SOUTH AFRICA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 344. SOUTH AFRICA BNP & NTPROBNP MARKET SI

Companies Mentioned

The companies profiled in this Bnp & Ntprobnp market report include:
  • Abbott Laboratories
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • bioMérieux PLC
  • Chengdu Illumaxbio Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio China Co., Ltd.
  • Gentian Diagnostics ASA
  • Getein Biotech, Inc.
  • QuidelOrtho Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Europe N.V.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.73 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

BNP and NTproBNP Market Report 2025 - Product Image

BNP and NTproBNP Market Report 2025

  • Report
  • 200 Pages
  • Global
From
BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast to 2030 - Product Image

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031 - Product Image

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

  • Report
  • 165 Pages
  • Global
From
Cardiac Marker Market by Product, Technology, Application, End User, Test Mode - Global Forecast to 2030 - Product Image

Cardiac Marker Market by Product, Technology, Application, End User, Test Mode - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.